{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:06:32Z","timestamp":1788303992972,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Second Edition of Key R&D"},{"name":"Sichuan Provincial Science and Technology Department","award":["2021YFS0165"],"award-info":[{"award-number":["2021YFS0165"]}]},{"name":"Hangzhou Tigermed Consulting Co., Ltd","award":["2019HX010"],"award-info":[{"award-number":["2019HX010"]}]},{"name":"North China Pharmaceutical Co., Ltd","award":["2020HX030"],"award-info":[{"award-number":["2020HX030"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>CTD-related immune thrombocytopenia (CTD-ITP) represents an unmet medical need because the drugs that are available are only partly effective and have considerable side-effects. The aim of this study was to assess the efficacy and safety of sirolimus in refractory CTD-ITP patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We did a single-arm, open-label, pilot study of sirolimus in patients with CTD-ITP unresponsive to, or intolerant of, conventional medications. Patients received oral sirolimus for 6\u2009months at a starting dose of 0.5\u20131\u2009mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6\u201315\u2009ng\/ml. The primary efficacy end point was changes in platelet count, and overall response assessed according to the ITP International Working Group Criteria. Safety outcomes included tolerance as assessed by the occurrence of common side-effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between November 2020 and February 2022, 12 consecutively hospitalized patients with refractory CTD-ITP were enrolled and prospectively followed. Of these, six patients (50%) achieved complete response, two (16.7%) achieved partial response, and four (33.3%) were no response under therapy. Three of four patients with primary Sj\u00f6gren's syndrome and two of three patients with systemic lupus erythematosus achieved overall response. One of two patients with overlapping Sj\u00f6gren's syndrome and systemic lupus erythematosus achieved complete response at 6\u2009months. No severe drug-related toxicities were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our results do support sirolimus as an alternative regimen for refractory CTD-ITP patients, including systemic lupus erythematosus and primary SS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead160","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T18:42:30Z","timestamp":1682016150000},"page":"79-84","source":"Crossref","is-referenced-by-count":14,"title":["Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4252-6559","authenticated-orcid":false,"given":"Hongjia","family":"Du","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China , Chengdu, China"},{"name":"Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital , Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China , Chengdu, China"},{"name":"Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital , Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4999-5048","authenticated-orcid":false,"given":"Jiang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China , Chengdu, China"},{"name":"Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital , Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-0978","authenticated-orcid":false,"given":"Jiarui","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China , Chengdu, China"},{"name":"Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital , Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-8728","authenticated-orcid":false,"given":"Dongze","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China , Chengdu, China"},{"name":"Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital , Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wubin","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China , Chengdu, China"},{"name":"Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital , Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-8714","authenticated-orcid":false,"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China , Chengdu, China"},{"name":"Department of Rheumatology and Immunology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital , Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"2024010500311353300_kead160-B1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"2024010500311353300_kead160-B2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N Engl J Med"},{"key":"2024010500311353300_kead160-B3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2011-12-309153","article-title":"How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment","volume":"120","author":"Ghanima","year":"2012","journal-title":"Blood"},{"key":"2024010500311353300_kead160-B4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"2024010500311353300_kead160-B5","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"2024010500311353300_kead160-B6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"2024010500311353300_kead160-B7","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"2024010500311353300_kead160-B8","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"key":"2024010500311353300_kead160-B9","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"key":"2024010500311353300_kead160-B10","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"2024010500311353300_kead160-B11","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"key":"2024010500311353300_kead160-B12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2024010500311353300_kead160-B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"2024010500311353300_kead160-B14","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1093\/rheumatology\/keaa645","article-title":"Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial","volume":"60","author":"Wu","year":"2021","journal-title":"Rheumatology"},{"key":"2024010500311353300_kead160-B15","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1093\/rheumatology\/keaa918","article-title":"Comment on: sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial","volume":"60","author":"Banday","year":"2021","journal-title":"Rheumatology"},{"key":"2024010500311353300_kead160-B16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024010500311353300_kead160-B17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024010500311353300_kead160-B18","first-page":"328","article-title":"Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients","volume":"16","author":"Alarc\u00f3n-Segovia","year":"1989","journal-title":"J Rheumatol"},{"key":"2024010500311353300_kead160-B19","first-page":"615","article-title":"Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria","volume":"17","author":"Mosca","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"2024010500311353300_kead160-B20","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"2024010500311353300_kead160-B21","doi-asserted-by":"crossref","first-page":"1759720x20953336","DOI":"10.1177\/1759720X20953336","article-title":"Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis","volume":"12","author":"Peng","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024010500311353300_kead160-B22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2013.07.016","article-title":"A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sj\u00f6gren's syndrome","volume":"171","author":"Shah","year":"2013","journal-title":"J Control Release"},{"key":"2024010500311353300_kead160-B23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/rheumatology\/kel010","article-title":"Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus","volume":"45","author":"Kuwana","year":"2006","journal-title":"Rheumatology"},{"key":"2024010500311353300_kead160-B24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2141.2010.08412.x","article-title":"Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters","volume":"152","author":"Toltl","year":"2011","journal-title":"Br J Haematol"},{"key":"2024010500311353300_kead160-B25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2141.2002.03817.x","article-title":"Platelet autoantibodies and lupus-associated thrombocytopenia","volume":"119","author":"Michel","year":"2002","journal-title":"Br J Haematol"},{"key":"2024010500311353300_kead160-B26","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/art.10420","article-title":"Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia","volume":"46","author":"Kuwana","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2024010500311353300_kead160-B27","doi-asserted-by":"crossref","first-page":"102171","DOI":"10.1016\/j.ceca.2020.102171","article-title":"Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca(2+)-CaMKII-dependent PTEN\/Akt-Erk1\/2 signaling pathway in normal and neoplastic B-lymphoid cells","volume":"87","author":"Zeng","year":"2020","journal-title":"Cell Calcium"},{"key":"2024010500311353300_kead160-B28","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"2024010500311353300_kead160-B29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12935-019-0779-0","article-title":"Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy","volume":"19","author":"Sun","year":"2019","journal-title":"Cancer Cell Int"},{"key":"2024010500311353300_kead160-B30","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/leu.2010.170","article-title":"Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies","volume":"24","author":"Chapuis","year":"2010","journal-title":"Leukemia"},{"key":"2024010500311353300_kead160-B31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.21037\/atm.2019.03.04","article-title":"Enhancing autophagy protects platelets in immune thrombocytopenia patients","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"key":"2024010500311353300_kead160-B32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.immuni.2014.08.011","article-title":"The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production","volume":"41","author":"Kobayashi","year":"2014","journal-title":"Immunity"},{"key":"2024010500311353300_kead160-B33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/0961203313485489","article-title":"Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature","volume":"22","author":"Jovancevic","year":"2013","journal-title":"Lupus"},{"key":"2024010500311353300_kead160-B34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/art.40380","article-title":"Blockade of treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus","volume":"70","author":"Kato","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024010500311353300_kead160-B35","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s10067-020-05152-x","article-title":"Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study","volume":"39","author":"Sun","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2024010500311353300_kead160-B36","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1038\/s41598-021-84493-2","article-title":"Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"2024010500311353300_kead160-B37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10875-015-0212-y","article-title":"Early complement component deficiency in a single-centre cohort of pediatric onset lupus","volume":"35","author":"Bhattad","year":"2015","journal-title":"J Clin Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead160\/50121673\/kead160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/1\/79\/55030519\/kead160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/1\/79\/55030519\/kead160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:31:58Z","timestamp":1704414718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/1\/79\/7133732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4,20]]},"published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead160","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,4,20]]}}}